0000000000605581

AUTHOR

David Grimwade

showing 4 related works from this author

Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with …

2010

We compared genomic breakpoints at the PML and RARA loci in 23 patients with therapy-related acute promyelocytic leukemia (t-APL) and 25 de novo APL cases.Eighteen of 23 t-APL cases received the topoisomerase II poison mitoxantrone for their primary disorder. DNA breaks were clustered in a previously reported 8 bp "hot spot" region of PML corresponding to a preferred site of mitoxantrone-induced DNA topoisomerase II-mediated cleavage in 39% of t-APL occurring in patients exposed to this agent and in none of the cases arising de novo (P = 0.007). As to RARA breakpoints, clustering in a 3' region of intron 2 (region B) was found in 65% of t-APL and 28% of de novo APL patients, respectively. S…

MaleCancer ResearchReceptors Retinoic AcidRetinoic AcidMessengerPromyelocytic Leukemia ProteinTranslocation GeneticChromosome BreakpointsLeukemia Promyelocytic Acuteimmune system diseasesReceptorsPromyelocyticGeneticsLeukemiabiologyReverse Transcriptase Polymerase Chain ReactionRetinoic Acid Receptor alphaNuclear ProteinsDNA NeoplasmMiddle AgedFemaleHumanAdultAcute promyelocytic leukemiaChromosome BreakpointsTranslocationAntineoplastic AgentsAcuteChromosomesYoung AdultPromyelocytic leukemia proteinGeneticGeneticsmedicineConsensus sequenceHumansRNA MessengerReceptors Retinoic Acid; Male; Young Adult; Middle Aged; Chromosome Breakpoints; Female; Chromosomes Human Pair 17; Tumor Suppressor Proteins; Humans; DNA Neoplasm; Translocation Genetic; Leukemia Promyelocytic Acute; Antineoplastic Agents; Nuclear Proteins; RNA Messenger; Mitoxantrone; Reverse Transcriptase Polymerase Chain Reaction; Chromosomes Human Pair 15; Transcription Factors; Aged; AdultneoplasmsAgedChromosomes Human Pair 15Pair 17Tumor Suppressor ProteinsTopoisomeraseBreakpointPair 15DNAmedicine.diseaseRetinoic acid receptor alphabiology.proteinNeoplasmRNAHuman genomeMitoxantroneSettore MED/15 - Malattie del SangueChromosomes Human Pair 17Transcription FactorsGenes, Chromosomes and Cancer
researchProduct

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia

2016

OncologyAcute promyelocytic leukemiaacute leukaemiamedicine.medical_specialtyacute promyelocytic leukaemiaPROTEÍNAS PROTO-ONCOGÊNICAS03 medical and health sciences0302 clinical medicineInternal medicinemedicineNeoplasmSurvival ratebusiness.industryFollow up studiesHematologymedicine.diseaseMinimal residual diseaseClinical trialLeukemiaPML/RARA; acute leukaemia; acute promyelocytic leukaemia; minimal residual disease; quantitative PCR030220 oncology & carcinogenesisquantitative PCRminimal residual diseaseAcute promyelocytic leukaemiabusinessPML/RARASettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

2015

In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74% in hematological and 62% in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-u…

MaleCancer ResearchInternational CooperationGastroenterologyArsenicalsEuropean LeukemiaNetchemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcuteRecurrence80 and overCumulative incidenceProspective StudiesRegistriesLeukocytosisArsenic trioxideChildAged 80 and overPromyelocyticLeukemiaCell DifferentiationOxidesHematologyMiddle AgedEuropeLeukemiaTreatment OutcomeOncologyChild PreschoolFemalemedicine.symptomAdultAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentAntineoplastic AgentsAcuteDisease-Free SurvivalYoung AdultInternal medicinemedicineHumansAutologous transplantationPreschoolAgedbusiness.industrymedicine.diseaseSurgeryTransplantationAdolescent; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Arsenicals; Cell Differentiation; Child; Child Preschool; Disease-Free Survival; Europe; Female; Humans; International Cooperation; Leukemia Promyelocytic Acute; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Registries; Treatment Outcome; Young AdultchemistrybusinessSettore MED/15 - Malattie del SangueLeukemia
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct